Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries. The company was incorporated in 1991 and is based in Uppsala, Sweden.
| 6.97 | |
| 6.37 | |
| - | |
| 6.57 | |
| 6.58 | |
| 6.28-16.8 | |
| 169 M | |
| 24 491 K | |
| 23 485 K | |
| -0.1394 | |
| 0.421 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Corline Biomedical AB (”Corline”) publicerar härmed delårsrapporten för perioden januari till september 2023. Nedan följer en kort sammanfattning av delårsrapporten. Fullständig rapport finn...
Corline Biomedical AB (”Corline”) meddelar härmed resultat efter uppföljning i 12 månader av behandlade patienter i RENAPAIR 01 samt vid jämförelse med transplanterade parnjurar. I septembe...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
